<abstract xmlns="http://www.w3.org/1999/xhtml"> Background: Breast angiosarcoma is a rare but aggressive vascular-origin soft tissue tumor. Surgery is the main treatment. However, recent evidence has shown activity of the single agents, paclitaxel or docetaxel, in unresectable or metastasis angiosarcoma.Objective: To report the case of a patient who received systemic chemotherapy as part of multidisciplinary approach to improve clinical outcome.Results: We report the case of a 56-year-old female patient who presented with a locally advanced primary angiosarcoma of the left breast and received a combination gemcitabine and docetaxel as neoadjuvant chemotherapy in addition to standard multidisciplinary treatment. The patient was followed for at least 20 months without evidence of disease recurrence.Conclusion: A perioperative combination chemotherapy consisting of docetaxel and gemcitabine can be considered as a strategy to achieve a pathological complete response and durable remission.</abstract>

Background: Breast angiosarcoma is a rare but aggressive vascular-origin soft tissue tumor. Surgery is the main treatment. However, recent evidence has shown activity of the single agents, paclitaxel or docetaxel, in unresectable or metastasis angiosarcoma.Objective: To report the case of a patient who received systemic chemotherapy as part of multidisciplinary approach to improve clinical outcome.Results: We report the case of a 56-year-old female patient who presented with a locally advanced primary angiosarcoma of the left breast and received a combination gemcitabine and docetaxel as neoadjuvant chemotherapy in addition to standard multidisciplinary treatment. The patient was followed for at least 20 months without evidence of disease recurrence.Conclusion: A perioperative combination chemotherapy consisting of docetaxel and gemcitabine can be considered as a strategy to achieve a pathological complete response and durable remission.

Neoadjuvant gemcitabine and docetaxel in primary breast angiosarcoma revealed complete pathological remission

Division of Medical Oncology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330,

MD, PhD, Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330,

Department of Radiology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330,

Department of Pathology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330,

Department of Surgery, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330,

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Background: Breast angiosarcoma is a rare but aggressive vascular-origin soft tissue tumor. Surgery is the main treatment. However, recent evidence has shown...

Neoadjuvant gemcitabine and docetaxel in primary breast angiosarcoma revealed complete pathological remission

Article Category: Clinical report

Pubblicato online: 04 feb 2017

Pagine: 449 - 454

DOI: https://doi.org/10.5372/1905-7415.0703.199

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.